Uveitis I: Green light - When do patients need immunomodulatory treatment?
My Session Status
At the end of this session, participants will be able to:
- Assess uveitis guidelines to determine when referral to a uveitis specialist or rheumatologist for immunomodulatory treatment is necessary to prevent complications.
- Describe a new class of therapy for uveitis, including its mechanism of action and clinical applications.
- Apply safe and effective uveitis therapies in pregnant patients, ensuring optimal management while considering maternal and fetal safety.
CanMEDS: Medical Expert, Collaborator
Sub Sessions
Author’s Name(s): Nupura Bakshi, Carlos Pavesio, Eric Suhler, Phoebe Lin, Meike Pauly- Evers, Daniela Willen, William Holmes, Federica Storti, Zeinab Barekati, Tatiana Gott, Benedicte Passemard, Lachlan Macgregor, Sumit Sharma, Sascha Fauser, Marina MesquidaAuthor’s Disclosure Block: Nupura Bakshi: Roche, Grant/research support, Bayer, Membership on an advisory panel, standing committee or board of directors, Biogen, Membership on an advisory panel, st...
Author’s Name(s): Evangelina Esposito, Christof Hänsli, Julie Vadboncoeur, Marie-Josée AubinAuthor’s Disclosure Block: Evangelina Esposito, none; Christof Hänsli, none; Julie Vadboncoeur, none; Marie-Josée Aubin, noneAbstract BodyPurpose: To present an educational case series on neoplastic and infections presenting as masquerade syndromes. Study Design: Retrospective observational case series and associated literature review...
Author’s Name(s): Tina Felfeli, Laura Rosella, Sherif El-Defrawy, Efrem D. Mandelcorn, Jessica WiddifieldAuthor’s Disclosure Block: Tina Felfeli, none; Laura Rosella, none; Sherif El-Defrawy, none; Efrem D. Mandelcorn, none; Jessica Widdifield, noneAbstract BodyPurpose: To identify individuals with uveitis using health administrative data in Ontario and support surveillance to analyze evolving trends in epidemiology and care...
Author’s Name(s): Jack Mouhanna, Sheetal Pundir, Jesia HasanAuthor’s Disclosure Block: Jack Mouhanna, none; Sheetal Pundir, none; Jesia Hasan, noneAbstract BodyPurpose:Immune checkpoint inhibitors and targeted therapies are the mainstay treatment for advanced melanoma. The combination of a BRAF kinase inhibitor (BRAFi) and a MEK kinase inhibitor (MEKi) is particularly effective in patients with melanoma harboring the common ...